Every tumor is unique. Thus, it is essential to know and understand the underlying molecular pathology of a tumor to treat it properly. With comprehensive genomic profiling (CGP), hundreds of genes and cancer-relevant biomarkers can be analyzed simultaneously. The chances of discovering actionable alterations are increased by simultaneously assessing all these genes and biomarkers. With this approach, results might be available faster, and input material of biopsy samples can be saved. One possibility to comprehensively profile a tumor is the TruSight™ Oncology 500 Assay. With this assay, 523 cancer-relevant genes are analyzed for single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variations (CNVs). Furthermore, the cancer-relevant biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI) are assessed. TMB measures the number of somatic mutations in a cancer patient’s tumor and is quantified as mutations per megabase (mut/Mb). MSI indicates failures of the DNA mismatch repair system.
The application areas of TSO500 are manifold and include:
- stratifying patients for the best treatment choice
- identifying patients eligible for clinical trials
- driving clinical research, especially in the area of immune therapy
You can choose between different TSO500 products for comprehensive genomic profiling of your tumor samples.
Our service covers the full project workflow: from expert consulting and comprehensive bioinformatic evaluation to a clear and structured project report. The project report provides insights into sample quality, sequencing parameters, bioinformatic analysis, and results.
CeGaT Is the Best Partner for Sequencing Your Project
Explore Our Product Portfolio for TSO500
We offer different TSO500 products to address a variety of research questions. Each of our products can be supplemented with further services. We are happy to advise you.
TSO500 | TSO500 ctDNA |
Species | Species |
Sequencing panel | Sequencing panel |
Number of analyzed genes | Number of analyzed genes |
Starting material | Starting material |
Sequencing platform | Sequencing platform |
Included deliverables | Included deliverables |
Bioinformatics
The raw sequencing data (FASTQ format) of TSO500 are automatically processed using the TSO500 (Illumina) pipeline. For TSO500 ctDNA, the DRAGEN-Pipeline (Illumina) is used. The analysis includes the alignment of trimmed sequencing data (BAM format), calling and annotation of SNVs and indels, and fusions (VCF, TSV, and JSON format). Furthermore, CNVs (VCF format) and the TMB/MSI status (TSV format) are evaluated. In addition to the data, a project report is generated (PDF file).
Technical Information
At CeGaT, paired-end sequencing is performed for TSO500 using 2 x 100 bp. For our TSO500 ctDNA product, paired-end sequencing with 2 x 150 bp is performed. The Illumina sequencing platforms are used for both products. If you require other sequencing parameters, please let us know! We can provide further solutions.
Gene Directory
Our Commitment to You
Fast Processing
Turnaround time
≤ 15 business days
High Quality
Highest accuracy for all processes
Secure Delivery
Secure provision of sequenced data via in-house servers
Safe Storage
Safe storage of samples and data after project completion
Downloads
Contact Us
Do you have a question or are you interested in our service? Feel free to contact us. We will take care of your request as soon as possible.
Start Your Project with Us
We are happy to discuss sequencing options and to find a solution specifically tailored to your clinical study or research project.
When getting in contact, please specify sample information including starting material, number of samples, preferred library preparation option, preferred sequencing depth and required bioinformatic analysis level, if possible.
